Journal of Clinical Oncology
Articles in this Issue
Chemotherapy selection for advanced or metastatic pancreatic cancer using machine learning models trained with multi-center datasets.
738 Background: Several factors must be considered when selecting the chemotherapeutic regimen for advanced or metastatic pancreatic cancer. The decision...
Molecular and clinical determinants of targeted therapy (TT) outcomes in biliary tract cancer (BTC): Analysis of a prospectively maintained next generation sequencing (NGS) biorepository.
555 Background: BTCs are genomically diverse. TT have established antitumor activity in a subset of pts that harbour actionable alterations; however, most...
Impact of baseline alterations in HER2-pathway oncogenic drivers on response to anti-HER2 therapy in patients (pts) with HER2-amplified advanced colorectal cancer (aCRC).
243 Background: HER2-amplified aCRC is associated with poor prognosis despite new anti-HER2 regimens. Insight on biomarkers that predict response to these...
Comparison of long-term outcomes for neoadjuvant chemoradiation (NA-CRT) followed by surgery versus (V) definitive chemoradiation (D-CRT) in localized gastroesophageal cancer (GEC): A single-center analysis.
371 Background: The therapeutic approach in locally advanced GEC is evolving. NA-CRT followed by surgery has been recommended based on the CRO...
Fruquintinib combined with FOLFIRI/mFOLFOX6 as second-line treatment in patients with RAS-mutant metastatic colorectal cancer (mCRC): A multicenter, open-label, phase II study.
151 Background: Anti-angiogenic drugs combined with chemotherapy could bring good clinical benefit to patients (pts) with mCRC, but the efficacy in pts wi...
A comparative study of dosage strategies in HIPEC: BSA-based vs fixed dose methods.
832 Background: Peritoneal metastases commonly occur in ovarian, gastric, and colorectal cancers, significantly contributing to patient morbidity and mort...
Real-world outcomes of targeted therapies and local interventions in BRAF V600E–mutated metastatic colorectal cancer: A single-center retrospective study.
203 Background: Metastatic colorectal cancer (mCRC) patients with BRAF V600E mutations, especially those with microsatellite stable (MSS) tumors, have poo...
Short-course radiation(SCRT) followed by 6 cycles of cadonilimab plus mFOLFOX6 as neoadjuvant therapy for patients with locally advanced rectal cancer (LARC): A multicenter, single arm, phase II trial (NeoCaCRT).
LBA210 Background: Preoperative chemoradiotherapy (CRT) followed by total mesorectal excision (TME) is recommended for mismatch re...
The influence of depression on esophageal cancer outcomes: Using the National Inpatient Sample (NIS) 2021.
338 Background: Esophageal cancer (EC) remains a challenging malignancy with high morbidity and mortality rates. Depression is prevalent among cancer pati...
The impact of prediabetes on cerebrovascular risk among patients with gastrointestinal malignancies.
817 Background: Cancer screening ingastrointestinal (GI) malignancies has translated into an improvement in overall survival due to detection at an earlie...
A multicenter, open-label, first-in-human study of TYRA-200 in advanced intrahepatic cholangiocarcinoma and other solid tumors with activating <i>FGFR2</i> gene alterations (SURF201).
TPS646 Background: Approved Fibroblast Growth Factor Receptor (FGFR) inhibitors have demonstrated clinical benefit in locally advanced or metastatic chola...
Safety and preliminary efficacy of ivaltinostat, an HDAC inhibitor, plus capecitabine in patients with pretreated metastatic pancreatic adenocarcinoma (mPDAC): Results of a phase Ib study.
742 Background: Front-line chemotherapy for patients (pts) with mPDAC typically consists of mFOLFIRINOX or gemcitabine/nab-paclitaxel given until disease...
A retrospective study of the prognostic value of early induction of S-1 postoperative adjuvant therapy for pancreatic cancer.
689 Background: The usefulness of oral S-1 administration as adjuvant therapy (AC) after pancreatic cancer surgery has been demonstrated (1). Our study al...
Prognostic factors for thermo-ablation of liver metastases in colon cancer: A Maltese perspective.
267 Background: Malta is a small Mediterranean archipelago with an annual colon cancer incidence of 300 patients per year and a cumulative 5-year overall...
Patterns of metastatic spread and survival outcomes for stage IV left-sided colon vs. rectal cancers: A real-world analysis.
75 Background: A growing body of literature has reported differences in biology, metastatic potential, and outcomes among patients with colorectal cancer...
Serum mucin 5AC (MUC5AC) as a predictor of outcomes and microscopic distant metastasis in pancreatic ductal adenocarcinoma (PDA).
767 Background: Our prior studies demonstrated that tissue extracellular MUC5AC (EM) detection (EM-D) is associated with early recurrence, and serum MUC5A...
Real-world evidence on genomic profiles and survival outcomes in patients with HER2-positive metastatic colorectal cancer.
58 Background: Patients (pts) with HER2-positive (HER2+) metastatic colorectal cancer (mCRC) represent a small, but increasingly important subgroup due to...
Evaluating novel therapies and circulating tumor DNA (ctDNA) as a marker of response in curatively treated gastrointestinal cancers with microscopic residual disease.
TPS850 Background: ctDNA can identify the earliest sign of relapse (MRD) after curative therapies with specificities of 93-100%, positive predictive value...
Tislelizumab (Tisle) combined with POFI (irinotecan, paclitaxel, oxaliplatin and 5-FU/levoleucovorin) as first-line treatment of advanced gastric/gastroesophageal junction adenocarcinoma (AGC): OS analysis results of the SYLT-023.
450 Background: Tisle is an anti-PD-1 antibody. The combination of Tisle + XELOX/FP is a first-line treatment of AGC in China. Both irinotecan and paclita...
Multi-site blinded validation of a deep learning approach for clinical-grade MSI/dMMR detection in colorectal cancer from H&E-stained pathology images.
44 Background: Testing for microsatellite instability (MSI) or mismatch repair deficiency (dMMR) is part of the diagnosis and clinical management of patie...
Patient-reported outcomes in GI cancer: Leading change to meet the needs of the gastrointestinal cancer community.
813 Background: According to the World Health Organization International Agency for Research on Cancer, globally gastrointestinal (GI) cancers account for...
Mortality and other outcomes of hospitalizations due to pancreatic cancer.
780 Background: Pancreatic cancer continues to be a highly fatal malignancy of the digestive system and imposes a significant financial strain on healthca...
Preclinical analysis and clinical validation to identify biomarkers for trifluridine/tipiracil (FTD/TPI) efficacy with or without bevacizumab in patients with metastatic colorectal cancer.
230 Background: We previously identified candidate biomarkers for FTD/TPI efficacy through preclinical and translational studies in patients with metastat...
Relationship in gene amplification between <i>ERBB2</i> and other oncogenes: Implications for the therapeutic efficacy of trastuzumab (Tmab)-based chemotherapy (CTx) in HER2 positive gastric cancer.
468 Background: This study aimed to elucidate the molecular characteristics, focusing on the co-amplification of ERBB2 and other o...
A comprehensive molecular and clinical study of patients with young-onset CRC.
235 Background: Young-onset colorectal cancer (YO-CRC), defined as colorectal cancer diagnosed in individuals under 50 years of age, has emerged as a dist...